

FILE 'HOME' ENTERED AT 12:41:55 ON 21 JAN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:42:21 ON 21 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4

DICTIONARY FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

*** YOU HAVE NEW MAIL ***

=>

Uploading C:\Program Files\Stnexp\Queries\10538904.str

L1 STRUCTURE UPLOADED

=> s l1 full

FULL SEARCH INITIATED 12:42:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2056 TO ITERATE

100.0% PROCESSED 2056 ITERATIONS

96 ANSWERS

SEARCH TIME: 00.00.01

L2 96 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 12:42:47 ON 21 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 20 Jan 2008 (20080120/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 2088 L2

=> s 13 and product? (5a) F (4a) tracer

3018025 PRODUCT?

641173 F

57095 TRACER

0 PRODUCT? (5A) F (4A) TRACER

L4 0 L3 AND PRODUCT? (5A) F (4A) TRACER

=> s 13 and 18F

7000 18F

L5 5 L3 AND 18F

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 5 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 bib abs 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:1089333 CAPLUS

DN 143:326552

TI Synthesis of [¹⁸F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers

AU Fei, Xiangshu; Wang, Ji-Quan; Miller, Kathy D.; Sledge, George W.; Hutchins, Gary D.; Zheng, Qi-Huang

CS Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

SO Nuclear Medicine and Biology (2004), 31(8), 1033-1041

CODEN: NMBIEO; ISSN: 0969-8051

PB Elsevier Inc.

DT Journal

LA English

OS CASREACT 143:326552

AB Xeloda (Capecitabine), a prodrug of antitumor agent 5-fluorouracil, is the first and only oral fluoropyrimidine to be approved for use as second-line therapy in metastatic breast cancer, colorectal cancer, and other solid malignancies. Fluorine-18 labeled Xeloda may serve as a novel radiotracer for positron emission tomog. (PET) to image enzymes such as thymidine phosphorylase and uridine phosphorylase in cancers. The precursor 2',3'-di-O-acetyl-5'-deoxy-5-nitro-N4-(pentyloxycarbonyl)cytidine (11) was synthesized from D-ribose and cytosine in 8 steps with approx. 18% overall chemical yield. The reference standard 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine (Xeloda; 1) was synthesized from D-ribose and 5-fluorocytosine in eight steps with approx. 28% overall chemical yield. The target radiotracer 5'-deoxy-5-[¹⁸F]fluoro-N4-(pentyloxycarbonyl)cytidine ([¹⁸F]Xeloda; [¹⁸F]1) was prepared by nucleophilic substitution of the nitro-precursor with K¹⁸F/Kryptofix 2.2.2 followed by a quick deprotection reaction and purification

with the HPLC method in 20-30% radiochem. yields.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:122359 CAPLUS

DN 124:219229

TI Monitoring gene therapy with cytosine deaminase: In vitro studies using tritiated-5-fluorocytosine

AU Haberkorn, Uwe; Oberdorfer, Franz; Gebert, Johannes; Morr, Iris; Haack, Karin; Weber, Klaus; Lindauer, Markus; Van Kaick, Gerhard; Schackert, Hans Konrad

CS Department Oncological Diagnostics and Therapy, German Cancer Research Center, Heidelberg, 69120, Germany

SO Journal of Nuclear Medicine (1996), 37(1), 87-94

CODEN: JNMEAQ; ISSN: 0161-5505

PB Society of Nuclear Medicine

DT Journal

LA English

AB Genetically modified mammalian cells that express the cytosine deaminase (CD) gene are able to convert the nontoxic prodrug 5-fluorocytosine (5-FC) to the toxic metabolite 5-fluorouracil (5-FU). PET with ^{18}F -5-FC may be used for in vivo measurement of CD activity in genetically modified tumors. A human glioblastoma cell line was stably transfected with the Escherichia coli CD gene. After incubation of lysates of CD-expressing cells and control cells with ^3H -5-FC high-performance liquid chromatog. (HPLC) was performed. The uptake of 5-FC was measured after various incubation times using therapeutic amts. of 5-FC. In addition, saturation and competition expts. with 5-FC and 5-FU were performed. Finally, the efflux was measured. We found that ^3H -5-FU was produced in CD-expressing cells, whereas in the control cells only ^3H -5-FC was detected. Moreover, significant amts. of 5-FU were found in the medium of cultured cells, which may account for the bystander effect observed in previous expts. However, uptake studies revealed a moderate and nonsaturable accumulation of radioactivity in the tumor cells, suggesting that 5-FC enters the cells only through diffusion. Although a significant difference in 5-FC uptake was seen between CD-pos. and control cells after 48 h of incubation, no difference was observed after 2 h of incubation. Furthermore, a rapid efflux could be demonstrated. 5-Fluorocytosine transport may be a limiting factor for this therapeutic procedure. Quantitation with PET has to rely more on dynamic studies and modeling, including HPLC anal. of the plasma, than on nonmodeling approaches.

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1988:492932 CAPLUS

DN 109:92932

TI Fluorination of pyrimidines. Part 2. Mechanistic aspects of the reaction of acetyl hypofluorite with uracil and cytosine derivatives

AU Visser, Gerard W. M.; Herder, Renella E.; De Kanter, Frans J. J.; Herscheid, Jacobus D. M.

CS RNC, Free Univ., Amsterdam, 1007 MC, Neth.

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1988), (5), 1203-7

CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 109:92932

AB The reaction of acetyl hypofluorite (AcOF) with uracil, cytosine, and some N-1-substituted derivs. dissolved in either acetic acid or water has been investigated. Anal. by radio HPLC using ^{18}F as a tracer, and by ^1H NMR revealed that a substituent at N-1 of uracil has a remarkable effect on the stability of the intermediate 6-acetoxy-5-fluoro-5,6-dihydrouracils. Substitution at N-1 of cytosine did not really enhance

the stability of the intermediate adducts. In addition, it was found that these cytosine adducts rapidly deaminate in water, yielding their corresponding uracil analog.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:185735 CAPLUS
DN 104:185735
OREF 104:29401a,29404a
TI Mechanism and stereochemistry of the fluorination of uracil and cytosine using fluorine and acetyl hypofluorite
AU Visser, Gerard W. M.; Boele, Saskia; Van Halteren, Bert W.; Knops, Gertrudis H. J. N.; Herscheid, Jacobus D. M.; Brinkman, Gerard A.; Hoekstra, Arend
CS Radio-Nuclide Cent. (RNC), Free Univ., Amsterdam, 1007 MC, Neth.
SO Journal of Organic Chemistry (1986), 51(9), 1466-71
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 104:185735
AB The products of the reaction of CH_3COOF and F_2 with uracil and cytosine dissolved in acetic acid and water were studied by using ^{18}F as a tracer. Apart from 5-fluorouracil and the 5,5-difluoro adducts, the ^1H NMR spectra of the crude reaction mixture showed the presence of two geometric isomers of both 5-fluoro-6-acetoxy-5,6-dihydrouracil and 5-fluoro-6-hydroxy-5,6-dihydrouracil. In the fluorination of cytosine, corresponding products were observed with the exception of the acetoxy adducts. For both reagents and for both substrates a radical-cation mechanism is proposed. The observed conversions of the acetoxy adducts of uracil are explained by an acylimine intermediary.

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:592398 CAPLUS
DN 103:192398
OREF 103:30921a,30924a
TI Synthesis and biodistribution of ^{18}F -5-fluorocytosine
AU Visser, G. W. M.; Boele, S.; Knops, G. H. J. N.; Herscheid, J. D. M.; Hoekstra, A.
CS Radio-Nuclide Cent., Free Univ., Amsterdam, 1007 MC, Neth.
SO Nuclear Medicine Communications (1985), 6(8), 455-9
CODEN: NMCODC; ISSN: 0143-3636
DT Journal
LA English
AB 5- ^{18}F fluorocytosine (I) was prepared by reaction of cytosine with ^{18}F acetylhypofluorite in AcOH with 20% radiochem. yield. Tissue distribution studies of I performed in sarcoma-bearing rats showed that I was stable in vivo for ≥ 4 h and was rapidly excreted by kidneys into the urine. I was not a good tumor-localizing agent with tumor-to-blood and -to-muscle ratios of only 1.

=>